Posted by Michael Wonder on 13 Sep 2016
New biosimilar can offer an effective and lower cost treatment option for Canadians living with rheumatoid arthritis and ankylosing spondylitis
12 September 2016 - Broader adoption of preferential listing for biosimilars as part of private drug programs can also create significant savings for most plan sponsors and plan members.
Merck announced today that Brenzyz (etanercept) received approval in Canada for the treatment of adult patients with moderate to severe rheumatoid arthritis and ankylosing spondylitis.
Brenzys is a biosimilar to the originator biologic Enbrel and the first subcutaneous anti-tumour necrosis factor (anti-TNF) biosimilar medicine available in Canada.
